{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-115226","form_type":"8-K","ticker":"IOVA","cik":"0001425205","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.030819+00:00","generated_at":"2026-06-08T14:28:43.960995+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Iovance reports Q3 net loss of $113.8M; BLA for lifileucel on track with PDUFA Feb 24, 2024","bullets":["Net loss of $113.8M ($0.46/share) vs $99.6M ($0.63/share) in Q3 2022; revenue of $0.5M from Proleukin acquisition.","FDA Priority Review of lifileucel BLA on track; PDUFA date Feb 24, 2024; pre-approval inspections completed.","Onboarding completed at ~30 ATCs for potential U.S. commercial launch of lifileucel as first approved TIL therapy.","Cash position of $427.8M at Sept 30, 2023; raised ~$203.2M in Q3 from offerings; cash expected to fund operations into 2025.","Regulatory submissions for lifileucel in Europe and Canada planned for 2024; IOV-LUN-202 NSCLC trial enrollment on track for completion H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-115226","json":"https://secwatch.observer/filing/0001104659-23-115226.json","markdown":"https://secwatch.observer/filing/0001104659-23-115226.md","text":"https://secwatch.observer/filing/0001104659-23-115226.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425205/000110465923115226/0001104659-23-115226-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425205/000110465923115226/tm2330006d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T14:28:43.960995+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4891485ab99e3025a3611fcfacaf657712e0f4f2","claim":"IOVANCE BIOTHERAPEUTICS, INC. reported financial results for third quarter and year-to-date 2023.","evidence_excerpt":"Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465923115226/0001104659-23-115226-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter and year-to-date 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}